Rene Russo - Dec 22, 2021 Form 4/A - Amendment Insider Report for Xilio Therapeutics, Inc. (XLO)

Role
CEO AND PRESIDENT, Director
Signature
/s/ Chris Frankenfield, Attorney-in-Fact
Stock symbol
XLO
Transactions as of
Dec 22, 2021
Transactions value $
$0
Form type
4/A - Amendment
Date filed
1/4/2022, 04:32 PM
Date Of Original Report
Dec 23, 2021
Previous filing
Oct 21, 2021
Next filing
Feb 24, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XLO Stock Option (right to buy) Award $0 +100K $0.00 100K Dec 22, 2021 Common Stock 100K $13.83 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option award was granted on December 22, 2021 and shall vest on January 1, 2022 with respect to 1/48th of the shares of common stock underlying the stock option and continue to vest in equal monthly installments thereafter until December 1, 2025.
F2 On December 23, 2021, the reporting person filed a Form 4 that inadvertently reported that the stock option shall continue to vest until December 1, 2026. This amendment is being filed solely to correct such date to December 1, 2025, as set forth in footnote 1.